Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05978557 · ClinicalTrials.gov registry record
Brain Slice Explants to Predict Drug Response in Brain Tumors
A clinical trial of Central Nervous System Tumor, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05978557 is a study of Central Nervous System Tumor that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 172-participant average among 5 other Central Nervous System Tumor trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05978557, a study of Central Nervous System Tumor, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This biospecimen collection study will evaluate the feasibility of engrafting and testing resected Central nervous system (CNS) tumors tumor tissue ex vivo to estimate drug response, in pediatric and adult subjects. CNS tumors display remarkable heterogeneity and unfortunately there are no reliable precision oncology platforms that can identify the most effective therapy for each patient. Recent work has demonstrated the success of functional precision oncology platforms using patient-derived explant (PDE) at predicting drug response in various cancers. Since PDEs maintain important aspects of tumor heterogeneity they may prove effective as functional models for CNS tumors. The purpose of this study is to explore the feasibility of using a novel PDE platform to generate drug sensitivity scores from patients with central nervous system tumors in Pediatric and adult subjects having low- or high-grade CNS tumors resected. The secondary objective is to estimate the proportion of successfully scaled PDEs generated per given tumor size.
Conditions Studied
Interventions
- OTHER Biospecimen collection
Study Locations (1)
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2028-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05978557
The ClinicalTrials.gov registry entry for NCT05978557 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 5 other Central Nervous System Tumor trials with a reported enrollment target (71% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Nervous System Tumor appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen collection is the first listed.
NCT05978557 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05978557 about?
NCT05978557 is a clinical study titled "Brain Slice Explants to Predict Drug Response in Brain Tumors". This biospecimen collection study will evaluate the feasibility of engrafting and testing resected Central nervous system (CNS) tumors tumor tissue ex vivo to estimate drug response, in pediatric and adult subjects. CNS tumors display remarkable heterogeneity and unfortunately there are no reliable ...
What is the current status of trial NCT05978557?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-07-27. Estimated completion is 2028-03-01.
What conditions does trial NCT05978557 study?
This clinical trial studies the following conditions: Central Nervous System Tumor.
What interventions are being tested in trial NCT05978557?
The interventions under investigation include: Biospecimen collection (OTHER).
Who is sponsoring clinical trial NCT05978557?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05978557 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Tissue Collection for Drug Screening and Bioanalysis
RECRUITING
-
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
RECRUITING · Phase 1
-
Somatic Mosaicism in Twins Discordant for Childhood Cancer
RECRUITING
-
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.